Physician profile
Andrei Damian
NPI 1679579346
$8,249.12
in general payments reported to CMS, 2019-2025
41 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $1,000 · 2021: $1,541 · 2022: $1,937 · 2023: $1,290 · 2024: $1,065 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,461.56 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $962.91 | 2019-2024 | Xarelto |
| Abbott Laboratories | $703.97 | 2019-2024 | Mitraclip, Cardiomems |
| Pfizer INC. | $629.12 | 2019-2025 | |
| Medtronic, INC. | $560.09 | 2021-2023 | Micra, Corevalve Evolut R, Endurant Iis |
| Biosense Webster, INC. | $357.11 | 2019-2020 | |
| Bardy Diagnostics, INC. | $320.00 | 2019-2022 | |
| Biotronik INC. | $292.72 | 2019-2020 | |
| Atricure, INC. | $274.37 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $273.99 | 2019-2025 | Farxiga |
| Heartflow, INC. | $253.75 | 2023-2024 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $248.80 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $182.09 | 2019-2023 | Repatha |
| Cleerly, INC. | $180.33 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Zoll Respicardia, INC. | $176.09 | 2019-2023 | Remede System |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrei Damian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.